{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '13.6.', 'Pharmacokinetic Analysis', 'The data obtained for PK evaluation will be assessed in several ways to determine if there are', 'clinically relevant shifts in the PK of either study treatment. For bortezomib, the data will be', 'subjected to a maximum a posteriori (MAP) Bayesian evaluation using the published steady-state', 'model for this agent given as a single agent. Data from both arms will be evaluated in this', 'fashion. Comparisons of the empirical Bayesian estimates of the clearance and derived AUC', 'values for bortezomib given as a single agent may be conducted. In addition, a simulation of the', 'expected time course of bortezomib may be generated and the observed bortezomib', 'concentrations may be compared against the expected simulated concentration range.', 'For selinexor, a MAP analysis using a previously developed model for selinexor may be made', 'and the resulting empirical Bayesian estimates compared with the historical results from', 'single-agent studies. Similarly, the observed selinexor data may be compared with the expected', 'simulated concentration ranges.', '13.7.', 'Safety Analysis', 'Safety analyses will be performed on the safety population, which includes all patients who', 'receive at least 1 dose of study treatment. Patients will be analyzed according to the treatment', 'they received.', 'Confidential', 'Page 100', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '13.7.1.', 'Analysis of the Key Secondary Safety Endpoint', '13.7.1.1. Peripheral Neuropathy Events', 'The analysis of the peripheral neuropathy events will be performed at the time of the second PFS', 'IA. Statistical significance of peripheral neuropathy endpoint will not be claimed until PFS has', 'reached significance.', 'Treatment differences for the incidence of any Grade >2 peripheral neuropathy events (the key', 'secondary safety endpoint) will be tested using the Cochran-Mantel-Haenszel (CMH) test,', 'stratified by the randomization stratification factors. The treatment difference will be assessed', 'using the safety population. The number and percentage of patients will also be summarized by', 'treatment arm (SVd versus Vd) along with the odds ratio and associated 95% CIs and the', 'Breslow-Day test will be performed to assess homogeneity of odds ratios across the strata. A', 'sensitivity analysis for the incidence of any Grade >2 peripheral neuropathy events will be', 'conducted on the safety population where all Grade >2 peripheral neuropathy events that occur', 'for Vd patients regardless of cross-over status will be included in the sensitivity analysis.', 'Similar analysis using the CMH test and the Breslow-Day test as described in Section 13.5.2 will', 'be repeated to assess the incidence of any Grade peripheral neuropathy events on the safety', 'population, as well as for Grades 2, 3, and 4 separately.', 'All peripheral neuropathy events may also be provided in a data listing.', '13.7.2.', 'Analyses of the Non-Key Secondary Safety Enppoints', '13.7.2.1. Study Treatment Exposure', 'The following study treatment exposure data will be summarized: duration of exposure, number', 'of cycles completed, percent compliance, dose intensity (defined as total study treatment', 'received divided by duration of exposure, presented in mg/week and mg/day), number of missed', 'doses, number of dose interruptions, duration of dose interruption, number of dose reductions,', 'and number of dose escalations. Additional definition and analysis details may be found in the', 'SAP.', '13.7.2.2. Adverse Events', 'AEs will be coded using the MedDRA and displayed in tables and listings using MedDRA SOC', 'and preferred term. The incidence rates of treatment-emergent AEs (TEAEs; separated by', 'relationship to study treatment as assessed by the Investigator and maximum severity), SAEs,', 'AEs of at least Grade 3 in severity using NCI CTCAE v. 4.03, treatment-related treatment-', 'emergent SAEs, AEs leading to withdrawal of study treatment, and AEs leading to death will be', 'summarized. TEAEs will be AEs that start or worsen on or after the first day dose of study', 'treatment, through 30 days after the last dose, or any event considered treatment-related by the', 'Investigator through the end of the study; related AEs will be AEs with an Investigator', 'determination of related to treatment.', 'AEs with partial dates will be assessed using the available date information to determine if', 'treatment-emergent using rules outlined in the SAP. AEs with completely missing dates will be', 'Confidential', 'Page 101', 'Version 4.0']\n\n###\n\n", "completion": "END"}